Target Neuro Centers Leverage EnClear's CSF access, recirculation, and monitoring capabilities to target neurology and neurosurgery programs at leading academic medical centers and health systems for pilots or early adoption. Position the device as addressing toxicity in CSF linked to neurodegenerative progression, with potential for measurable patient outcomes. Recommend a targeted outreach plan to stakeholder groups (neurosurgery, neurology, clinical affairs, procurement) and development of clinical case studies to support adoption.

CNS Drug Partnerships Position EnClear as a strategic partner for CNS drug developers and biotech companies pursuing intrathecal therapies or CSF clearance approaches. Opportunities include co-development, licensing, or exclusive distribution arrangements that align regulatory timelines and clinical trial plans, enabling combined devices and therapeutics that improve delivery and monitoring in neurodegenerative diseases.

Clinical Trial Access Develop a clear pathway for early access programs or investigator-initiated trials with academic centers to build real-world evidence. Create a playbook for investigator recruitment, regulatory alignment, and endpoints focused on CSF toxicity clearance and continuous monitoring, facilitating first-in-human or early clinical studies.

Reimbursement Strategy Build a health economics and reimbursement plan that demonstrates the device's value in CNS care, including potential cost-offsets from toxicity removal and reduced complications. Target payer conversations early, gather data from pilots or trials, and prepare ROI models and real-world evidence to support hospital and system coverage decisions.

Regional Scale Capitalize on a US Northeast footprint and a lean team by pursuing regional partnerships, OEM or distributor arrangements, and licensing discussions with mid- to large-scale medtech players to accelerate manufacturing, commercialization, and service capabilities within targeted hospital networks.